Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1923-1926

  Gennatas, C ^a,b   Michalaki, V ^a   Gennatas, S ^a   Papalambros, E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Capecitabine; Colorectal cancer; First line therapy; Irinotecan

Indexed keywords

CAPECITABINE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 45949094172     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30,2005.
2. Backus HH, Wouters D, van der Wilt CL, Kuiper CM, van Groeningen CJ, Pinedo HM and Peters GJ: Thymidylate synthase inhibition induces p53 dependent and independent cell death. Adv Exp Med Biol 486: 303-306, 2000.
3. Mayer RJ: Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J Clin Oncol 19: 4093-4096, 2001.
4. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Pérez-Manga G, Rosso R, Rougier P and Schilsky RL: Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575, 2002.
5. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C and Harper P: Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
6. Cassidy J, Tabernero J, Twelves C, Brunei R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E and Díaz-Rubio E: XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091, 2004.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047, 2000.
8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
9. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
10. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
11. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A and Buzzoni R: Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100: 279-287, 2004.
12. Grothey A, Jordan K, Kellner O, Constantin C, Dittrich G, Kroening H, Mantovani L, Schlichting C, Forstbauer H and Schmollet HJ: Randomized phase II trial of capecitabine plus irinotecan (Capiri) vs. capecitabine plus oxaliplatin (CapOx) as first line therapy of advanced colorectal cancer (ACRC). J Clin Oncol 22: 255, (suppl, abstr 1022), 2003.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
14. National Cancer Institute: Common Toxicity Criteria Manual, Version 2. Bethesda, MD, National Cancer Institute, 2002.
15. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
16. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunate S, Mancarella S and Brunetti C: Gruppo Oncologico Dell'Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875, 2005.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
18. Park SH, Bang SM, Cho EK, Baek JH, Oh JH, Im SA, Park YS, Shin DB and Lee JH: First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology 66: 353-357, 2004.
19. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D and Roth AD: Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity. Ann Oncol 16: 282-288, 2005.
20. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B and Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 30: 4779-4786, 2007.
21. Cartwright T, Lopez T, Vukelja SJ, Encarnacion C, Boehm KA and Asmar L: Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5: 50-56, 2005.
22. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO and Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19: 2282-2292, 2001.
23. Hochster HS, Hart LL, Ramanathan RK et al: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE Study. J Clin Oncol 24: 148s, 2006.